Flag of the European Union EU Clinical Trials Register Help

Clinical trials for KD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: KD. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-004433-17 Sponsor Protocol Number: 124210 Start Date*: 2020-02-18
    Sponsor Name:MRC CTU at UCL
    Full Title: Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary arte...
    Medical condition: Kawasaki Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) EE (Completed) SE (Completed) FI (Completed) ES (Ongoing) DE (Completed) NL (Completed) IT (Completed) AT (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003194-22 Sponsor Protocol Number: APHP200009 Start Date*: Information not available in EudraCT
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RETREATMENT, IN PATIENTS WITH KAWASAKI DISEASE WHO FAILED TO RESPOND ...
    Medical condition: Anakinra treatment is expected to reduce the early and long-term mortality of patients with Kawasaki Disease (KD), by a rapid and sustained effect on vascular inflammation.
    Disease:
    Population Age: Infants and toddlers, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000928-37 Sponsor Protocol Number: 64007957MMY3006 Start Date*: 2023-02-15
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Mult...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005940-99 Sponsor Protocol Number: PERICO Start Date*: 2007-03-03
    Sponsor Name:vicente soriano
    Full Title: Open, multicentral and randomized study of phase IV to evaluate efficacy and safety to extent of treatment with Peginterferon alpha-2a (40 KD) combined with high doses of Ribavirin with support of ...
    Medical condition: hepatitis C in patients co infected with HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002715-41 Sponsor Protocol Number: P130934 Start Date*: 2015-08-11
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: KAWAKINRA study, "A phase IIa multicenter trial to assess the efficacy and safety of Anakinra in patients with intraveinous immunoglobulin-resistant Kawasaki disease"
    Medical condition: Anakinra treatment is expected to reduce the early and long term mortality of patients with Kawasaki Disease (KD), by a rapid and sustained effect on vascular inflammation
    Disease: Version SOC Term Classification Code Term Level
    17.1 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004185-34 Sponsor Protocol Number: 54767414MMY2065 Start Date*: 2019-05-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Mu...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) FR (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002767-30 Sponsor Protocol Number: ACT17453 Start Date*: 2023-02-23
    Sponsor Name:Sanofi-aventis recherche & developpement
    Full Title: A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory ...
    Medical condition: Relapsed/refractory multiple myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004864 10086466 Relapsed/refractory multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003222-76 Sponsor Protocol Number: ZX008-2103 Start Date*: 2022-08-19
    Sponsor Name:Zogenix International Limited
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EXAMINE THE EFFICACY AND SAFETY OF ZX008 IN SUBJECTS WITH CDKL5 DEFICIENCY DISORDER FOLLOWED BY AN OPEN-LABE...
    Medical condition: CDKL5 DEFICIENCY DISORDER
    Disease: Version SOC Term Classification Code Term Level
    22.1 10010331 - Congenital, familial and genetic disorders 10083005 CDKL5 deficiency disorder PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) DE (Trial now transitioned) FR (Not Authorised) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001396-33 Sponsor Protocol Number: EPA-COV-001 Start Date*: 2020-11-13
    Sponsor Name:SLA Pharma (UK) Ltd [...]
    1. SLA Pharma (UK) Ltd
    2. KD Swiss GmbH
    Full Title: A randomised, double-blind, placebo-controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004203-41 Sponsor Protocol Number: 54767414MMY2040 Start Date*: 2018-04-26
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-003409-18 Sponsor Protocol Number: RRC-2/3-2006 Start Date*: 2006-11-20
    Sponsor Name:Sahlgrenska University Hospital, Östra
    Full Title: An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Ch...
    Medical condition: chronic hepatitis C (CHC) virus infection genotype 2 or 3 who responded during (i.e. had HCV-RNA < 50 IU/mL at the end of previous therapy), but relapsed after (i.e. had detectable HCV-RNA after th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002713-40 Sponsor Protocol Number: MRZ60201-GL-3002 Start Date*: 2008-11-06
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, multicenter, randomized, rater- and subject-blind, parallel group trial to investigate the non-inferiority of NT 201, free of complexing proteins, in comparison with Clostridium botu...
    Medical condition: Treatment of glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    10.1 10052609 LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000549-73 Sponsor Protocol Number: MRZ 60201-GL-3001 Start Date*: 2008-05-15
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, open-label, international, multicenter trial to investigate the efficacy and safety of NT 201, free of complexing proteins, in the treatment of glabellar frown lines
    Medical condition: Treatment of glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    10.1 10052609 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003362-27 Sponsor Protocol Number: WO17.123 Start Date*: 2018-03-02
    Sponsor Name:OLVG
    Full Title: Ketanserin effects on Peripheral Temperature and Lactate
    Medical condition: Critical illness Delta temperature greater than 6.0 °C
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001243-55 Sponsor Protocol Number: CONTRA Start Date*: 2006-07-07
    Sponsor Name:Miguel Santin Cerezales
    Full Title: Open, multicenter, phase IV study to evaluate the safety and effectiveness of peginterferon alfa-2a (40 KD) associated with ribavirin for the treatment chronic hepatitis C with persistent normal AL...
    Medical condition: Comparate the safety and effectivenes of the treatment with peginterferon alfa-2a in combination with ribavirin between HIV/HCV coinfected patients with persistent normal ALT levels versus HIV/HCV ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002628-26 Sponsor Protocol Number: ZX008-1601 Start Date*: 2018-07-23
    Sponsor Name:Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc.
    Full Title: A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochlo...
    Medical condition: Lennox-Gastaut Syndrome in Children and Adults
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Ongoing) AT (Prematurely Ended) DK (Completed) GB (GB - no longer in EU/EEA) IT (Completed) SE (Completed) NL (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004340-30 Sponsor Protocol Number: M15-538 Start Date*: 2020-06-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005047-32 Sponsor Protocol Number: H-100-002 Start Date*: 2018-09-27
    Sponsor Name:Hookipa Biotech GmbH
    Full Title: A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero...
    Medical condition: Prevention of clinically significant cytomegalovirus (CMV) infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10072247 Cytomegalovirus immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) FR (Completed) AT (Completed) NO (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005536-17 Sponsor Protocol Number: UX007G-CL301 Start Date*: 2017-05-17
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1...
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10061032 Carbohydrate transport disorder LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005342-36 Sponsor Protocol Number: MRZ 60201-0609/1 Start Date*: 2007-06-11
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, open-label, multicenter, repeat-dose trial to investigate the safety and efficacy of NT 201, free of complexing proteins, in the treatment of glabellar frown lines
    Medical condition: Treatment of glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:38:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA